Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated, commercial-stage biotechnology company, will host a conference call and webcast on Monday, Nov. 9, 2026, at 8:30 a.m. ET to report its third-quarter 2026 financial results and operational highlights. The announcement matters because it gives investors their first quarterly look at how the company is executing on the commercial launch of TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), its newly approved flagship medicine and the first new treatment for fibromyalgia in more than 15 years.
Investors and interested parties can register to participate in the conference call or view the webcast through the company. A replay will be available under “IR Events” in the Investors section of the Tonix website. The full press release is available at https://nnw.fm/va44Q.
The timing of the update is significant. Tonix describes itself as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). The Nov. 9 call will therefore be a key checkpoint for assessing whether that infrastructure is translating into revenue and market penetration for TONMYA.
Beyond the commercial portfolio, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The company’s CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In addition, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The company notes that its product development candidates are investigational new drugs or biologics and that their efficacy and safety have not been established and they have not been approved for any indication. That caveat is important for investors weighing the pipeline’s potential against the risks inherent in clinical development.
The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. NNW is one of 75+ brands within the Dynamic Brand Portfolio at IBN.
For investors, the Nov. 9 report arrives at a pivotal moment. With TONMYA approved and marketed, the quarterly update will show whether Tonix can convert a first-in-15-years fibromyalgia treatment into durable commercial traction while simultaneously funding a pipeline that spans CNS and immunology. Full terms of use and disclaimers applicable to the content are available at https://www.NetworkNewsWire.com/Disclaimer.
